The insider purchase is too small to move the stock or signal strong conviction. Traders should focus on pipeline catalysts such as clinical trial readouts or regulatory updates for OKYO's NCP and eye disease programs rather than minor insider activity.
Price Chart
Executive Summary
OKYO Pharma issued a press release announcing that Non-Executive Director John Brancaccio purchased 5,000 ordinary shares at $1.48 per share, for a total of $7,400, increasing his holdings to 35,201 shares. The purchase is small and not material relative to the company's $49M market cap, offering negligible signal for stock movement.
Key Financial Metrics
Key Facts
- Non-Executive Director John Brancaccio purchased 5,000 ordinary shares at $1.48 per share on Nasdaq.
- Total purchase value: $7,400.
- Brancaccio's total holding increased to 35,201 shares.
- OKYO Pharma is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain and anterior segment eye diseases.
- Market cap is approximately $49M, making the insider purchase ~0.015% of market cap.
Financial Impact
Negligible — $7,400 insider purchase represents a tiny fraction of market cap and is not material.
Risk Factors
- OKYO is a clinical-stage biotech with no approved products, carrying typical development and regulatory risks.
- Past stock performance on similar filings has been poor; the company may face ongoing volatility and negative drift.
- Trivial insider purchases do not offset fundamental operational or financing risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3332413 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 6-K | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Oct 6, 2026 21d ago | Press Release | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Sep 29, 2026 28d ago | 6-K | $1.36 $1.29 | ▼ −5.15% | ▼ −4.94% | $1.49 (+9.56%) |
Sep 8, 2026 7w ago | 6-K | $1.53 $1.45 | ▼ −5.23% | ▼ −4.76% | $1.49 (−2.61%) |
Aug 7, 2026 11w ago | Insider Cluster | $1.57 $1.52 | ▼ −3.18% | ▼ −2.87% | $1.49 (−5.10%) |
Jul 28, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▲ +1.54% | $1.49 (−9.15%) |
Jul 27, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▼ −0.24% | $1.49 (−9.15%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | Press Release | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers